Download - An exploratory analysis of the crash 2 rct
![Page 1: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/1.jpg)
1
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
CRASH-2 trial collaborators Lancet 2011; 377: 1096–101
![Page 2: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/2.jpg)
2
Background
CRASH-2 trial collaborators Lancet 2010; 376: 23–32
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
![Page 3: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/3.jpg)
3
Methods
• Randomised controlled trial• Active vs placebo• Undertaken in 274 hospitals in 40 countries randomised
20,211• Randomisation was balanced by centre, with an
allocation sequence based on a block size of eight, generated with a computer random number generator
• Participants and study staff (site investigators and trial coordinating centre staff) were masked to treatment allocation
• All analyses were by intention to treat• Commenced May 2005 results published June 2010
![Page 4: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/4.jpg)
4
Eligibility criteria
• Inclusion criteria– Adult 16+– Trauma
• blunt• penetrating
– Significant bleeding as evidenced by SBP < 90 mmHg and/or heart rate > 110 bpm
• Exclusion criteria– Doctor’s discretion
• TEA clearly indicated• TEA clearly contraindicated
![Page 5: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/5.jpg)
5
Were all patients who entered the trial accounted for?
![Page 6: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/6.jpg)
6
Were all patients analysed in the groups to which they
were randomised? • All analyses were by intention to treat
minus withdrawn consent, minus no outcome data
![Page 7: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/7.jpg)
7
Were measures objective or were the patients and clinicians kept “blind” to which treatment
was being received? • Tranexamic acid and placebo ampoules
were indistinguishable.
![Page 8: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/8.jpg)
8
Was the assignment of patients to treatments randomised?
• Randomisation was balanced by centre, with an allocation sequence based on a block size of eight, generated with a computer random number generator.
• In hospitals in which telephone randomisation was not practicable we used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs.
• Hospitals with reliable telephone access used the University of Oxford Clinical Trial Service Unit (CTSU) telephone randomisation service.
![Page 9: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/9.jpg)
9
Were the groups similar at the start of the trial?
• Treatment groups were balanced with respect to all baseline patient characteristics (table 1; the webappendix p 1 shows baseline data of patients with follow-up).
![Page 10: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/10.jpg)
10
Aside from the allocated treatment, were groups treated equally?
![Page 11: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/11.jpg)
11
How large was the treatment effect?
Relative Risk (RR) = risk of the outcome in the treatment group / risk of the outcome in the control group
![Page 12: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/12.jpg)
12
How large was the treatment effect?
Relative Risk (RR) = risk of the outcome in the treatment group / risk of the outcome in the control group
![Page 13: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/13.jpg)
13
Absolute Risk Reduction (ARR)
![Page 14: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/14.jpg)
14
Absolute Risk Reduction (ARR)
ARRAC = 0.16 – 0.145 = 0.015 or 1.5%
ARRB = 0.057 – 0.049 = 0.008 or 0.8%
![Page 15: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/15.jpg)
15
Relative Risk Reduction (RRR)
![Page 16: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/16.jpg)
16
Relative Risk Reduction (RRR)
RRRAC = 1 – 0.91 = 0.09 or 9%
RRRB = 1 – 0.85 = 0.15 or 15%
![Page 17: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/17.jpg)
17
Number Needed to Treat (NNT)
![Page 18: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/18.jpg)
18
Number Needed to Treat (NNT)
NNTAC = 1 / (0.16 – 0.145) = 67(40-198)
NNTB = 1 / (0.057 – 0.049) = 125(69-450)
![Page 19: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/19.jpg)
19
Background to the exploratory analysis
• The original hypothesis was that TEA exerts its beneficial effect on 28 day mortality by inhibition of fibrinolysis leading to improved effectiveness of homeostasis
• But – no significant difference was recorded in transfusion requirements between TEA and placebo groups, and the CRASH-2 trial did not measure the effect of TEA on fibrinolytic assays
• Also there had been discussion about which trauma patients should be treated with TEA as no strong evidence emerged from the 1st analysis for any subgroup benefit in terms of all cause mortality
![Page 20: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/20.jpg)
20
Intial PICO - Research Question
P Adult trauma patients with, or at risk of, significant bleeding, treated within 8h of injury I Tranexamic acid (loading dose 1g over 10min then infusion of 1g over 8h)C Placebo (0.9% saline)O Death in hospital, within 28 days of injury
Research question - Among adult trauma patients with, or at risk of, significant bleeding, treated within 8h of injury is a lower 28 day in-hospital mortality rate achieved using tranexamic acid compared to placebo?
![Page 21: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/21.jpg)
21
Initial analysis
![Page 22: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/22.jpg)
22
Initial analysis
Post hoc change from <1
![Page 23: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/23.jpg)
23
New PICO - Research Question
P Adult trauma patients with, or at risk of, significant bleeding, treated within 8h of injury I Tranexamic acid (loading dose 1g over 10min then infusion of 1g over 8h)C Placebo (0.9% saline)O Death in hospital due to bleeding, within 28 days of injury
Research question - Among adult trauma patients with, or at risk of, significant bleeding, treated within 8h of injury is a lower 28 day in-hospital mortality due to bleeding rate achieved using tranexamic acid compared to placebo?
![Page 24: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/24.jpg)
24
Results
![Page 25: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/25.jpg)
25
Patient characteristics by time to treatment
![Page 26: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/26.jpg)
26
Patient characteristics by time to treatment
![Page 27: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/27.jpg)
27
Patient characteristics by time to treatment
![Page 28: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/28.jpg)
28
Patient characteristics by time to treatment
![Page 29: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/29.jpg)
29
Patient characteristics by time to treatment
• Type of injury?
![Page 30: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/30.jpg)
30
Death due to bleeding by subgroup
![Page 31: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/31.jpg)
Death due to all cause by subgroup
![Page 32: An exploratory analysis of the crash 2 rct](https://reader036.vdocument.in/reader036/viewer/2022062511/54bf8e7a4a79592b0a8b45b3/html5/thumbnails/32.jpg)
32
Will the results help me in caring for my patient?
• Is my patient so different to those in the study that the results cannot apply?
• Is the treatment feasible in my setting?
• Will the potential benefits of treatment outweigh the potential harms of treatment for my patient?